
Loading, please wait...

Loading, please wait...

Managing inflammatory bowel disease requires durable symptom control and long-term treatment persistence. In recent years, the clinical adoption of upadacitinib in ulcerative colitis has transformed modern gastroenterology practice. Although conventional biologic therapies offer substantial initial benefits, secondary loss of response remains a pervasive challenge. Consequently, many patients require frequent therapeutic switches over time. Recent real-world evidence now provides crucial insights into long-term drug retention across modern advanced therapies.
Real-world observational cohorts provide invaluable insights into routine clinical practice outside rigorous clinical trials. A recent retrospective cohort study evaluated administrative claims from the Merative MarketScan US commercial and Medicare databases. The study tracked patients from January 2022 through October 2025 across diverse healthcare environments. Specifically, investigators analyzed 946 adult patients with ulcerative colitis who initiated advanced therapy. The cohort included 164 patients starting upadacitinib, 475 initiating adalimumab, and 307 starting infliximab. Furthermore, researchers evaluated clinical patterns over a continuous 24-month observation period after the index date. The team examined both biologic-naive patients and individuals with previous advanced therapy exposure. To control for confounding variables, investigators conducted multivariable regression analyses. They adjusted for baseline disease severity, demographic differences, and concurrent corticosteroid use. The primary endpoints measured medication adherence and switching rates to alternative advanced therapies. Ultimately, this methodology offered an objective assessment of drug durability under real-world conditions. Consequently, the findings reflect meaningful routine clinical outcomes rather than idealized clinical trial settings.
Treatment switching often serves as a practical surrogate for therapeutic failure or unacceptable intolerance. Notably, the study revealed substantial differences in 24-month switch rates between oral upadacitinib and injectable biologics. Patients initiating upadacitinib achieved a remarkably low switch rate of only 20.1% over two years. In contrast, patients receiving tumor necrosis factor inhibitors switched far more frequently. Specifically, 49.2% of infliximab patients and 49.7% of adalimumab patients switched to another advanced therapy. Furthermore, multivariable regression models confirmed that the adjusted odds of switching were significantly higher for anti-TNF agents. These findings remained consistent in both bio-naive and bio-experienced cohorts. Clinicians often observe secondary loss of response with monoclonal antibodies due to anti-drug antibody formation. Because upadacitinib is a small molecule inhibitor, it does not elicit neutralizing immunogenic antibodies. Consequently, patients maintain therapeutic blood concentrations without immunogenic clearance. Therefore, upadacitinib offers superior long-term persistence compared to traditional anti-TNF biologics. These real-world outcomes confirm that targeted Janus kinase inhibition prevents treatment exhaustion in complex colitis.
Medication adherence remains vital for maintaining deep mucosal healing and avoiding disease flares. However, chronic therapy adherence often declines significantly during extended treatment courses. The MarketScan claims data tracked refill consistency using proportion of days covered metrics. Importantly, upadacitinib demonstrated robust treatment adherence and persistence throughout the 24-month evaluation period. While subcutaneous biologics require cold-chain management, once-daily oral tablets eliminate complex administration routines. Similarly, intravenous infliximab requires scheduled infusion center visits that disrupt work schedules. Thus, oral administration removes substantial logistical barriers for active adults. Moreover, upadacitinib delivers rapid symptomatic relief, often within days of treatment initiation. When patients experience prompt symptom resolution, their commitment to daily therapy strengthens. Consequently, sustained adherence directly correlates with reduced emergency room visits and fewer hospitalizations. Furthermore, sustained adherence reduces cumulative steroid exposure, protecting patients from steroid-related toxicities. Ultimately, oral administration and rapid clinical efficacy combine to support dependable long-term disease management.
Understanding the pharmacological distinctions between targeted small molecules and biologics explains these outcome differences. Monoclonal antibodies block single cytokine pathways extracellularly. While this mechanism reduces inflammation initially, parallel inflammatory pathways often activate to cause clinical relapse. In contrast, upadacitinib selectively inhibits Janus kinase-1 enzymes inside immune cells. By targeting Janus kinase-1, it interrupts downstream signaling for multiple cytokines, including interleukin-6 and interferon-gamma. Furthermore, small molecule inhibitors exhibit predictable pharmacokinetics regardless of serum albumin concentrations. Patients with active colitis often lose significant protein through inflamed intestinal mucosa, which accelerates biologic clearance. Because upadacitinib does not depend on protein-losing enteropathy clearance mechanisms, blood concentrations remain stable. Additionally, clinicians do not need to co-prescribe immunomodulators like azathioprine to prevent anti-drug antibodies. Thus, upadacitinib maintains broad inflammatory suppression with exceptional pharmacokinetic stability over extended treatment courses. Therefore, patients achieve consistent biological disease suppression without fluctuating pharmacokinetic trough levels.
These real-world findings offer valuable guidance for gastroenterologists managing ulcerative colitis in India. Inflammatory bowel disease prevalence is rising rapidly across Indian healthcare centers. Historically, anti-TNF biosimilars served as initial advanced therapy due to widespread availability. However, anti-TNF biologics carry substantial risks in regions with high endemic tuberculosis burden. While all advanced therapies require rigorous tuberculosis screening, oral small molecules eliminate cold-chain refrigeration risks. Indian patients frequently face unreliable domestic refrigeration during peak summer months. Furthermore, avoiding infusion center costs reduces out-of-pocket medical expenditures for self-paying families. Before prescribing upadacitinib, clinicians must complete mandatory screening for latent tuberculosis, viral hepatitis, and baseline dyslipidemia. Physicians should also administer recombinant zoster vaccination to reduce shingles risk. Routine follow-up should monitor complete blood counts, hepatic panels, and lipid profiles. Moreover, careful patient selection ensures that clinical benefits far outweigh potential infectious or vascular complications. Consequently, adopting upadacitinib provides Indian gastroenterologists with a durable, patient-friendly therapeutic option.
Upadacitinib demonstrated significantly lower switch rates primarily due to its distinct oral small-molecule pharmacology and lack of immunogenicity. Unlike monoclonal antibodies such as infliximab or adalimumab, upadacitinib does not induce neutralizing anti-drug antibodies, which frequently cause secondary loss of response. Furthermore, it simultaneously inhibits multiple inflammatory cytokines via selective Janus kinase-1 blockade, ensuring sustained symptom control, durable mucosal healing, and superior treatment persistence over a 24-month real-world timeframe.
Real-world evidence indicates that oral administration with upadacitinib supports higher patient adherence and persistence compared with injectable therapies. Subcutaneous injections and intravenous infusions require strict cold-chain storage, clinic visits, and complex administration schedules. In contrast, a once-daily oral tablet eliminates significant logistical burdens and travel expenses for working patients. When combined with rapid symptomatic improvement, this oral simplicity encourages patients to maintain consistent daily adherence throughout long-term maintenance therapy.
Before initiating upadacitinib therapy, clinicians must perform comprehensive baseline evaluations to minimize potential adverse risks. Essential pre-treatment screening includes testing for latent or active tuberculosis, hepatitis B, hepatitis C, and baseline lipid profiles. Additionally, physicians should evaluate complete blood counts and liver function while reviewing cardiovascular risk factors and thromboembolic history. Administering the recombinant zoster vaccine prior to treatment is also highly recommended to prevent herpes zoster reactivation during therapy.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A 24-month real-world study reveals that upadacitinib achieves significantly lower switch rates (20.1%) than infliximab (49.2%) and adalimumab (49.7%) in ulcerative colitis, demonstrating superior adherence and long-term durability in both bio-naive and bio-experienced cohorts.
Today

The GESS-AEEM consensus establishes a clear clinical implementation framework for testosterone therapy in postmenopausal women with hypoactive sexual desire disorder, focusing on transdermal dosing, precise laboratory monitoring, and safety communication.
Today

A Bayesian component network meta-analysis of 130 RCTs reveals that self-monitoring and gamification provide the clearest positive effects in mHealth physical activity interventions, while social comparison may have adverse psychological trade-offs.
Today

A paired cadaveric study compared triple and quintuple percutaneous Achilles tendon lengthening. While quintuple hemisection showed numerically greater elongation, differences were not statistically significant.
2 days back

A systematic review and meta-analysis evaluates the clinical outcomes of metformin in patients with advanced chronic kidney disease, assessing all-cause mortality, cardiovascular endpoints, end-stage kidney disease progression, and the true incidence of lactic acidosis in clinical practice.
Today